Biologic markers of chronic GVHD

Biologic markers of chronic GVHD may provide insight into the pathogenesis of the syndrome, identify molecular targets for novel interventions, and facilitate advances in clinical management. Despite extensive work performed to date largely focused on prediction and diagnosis of the syndrome, little synthesis of findings and validation of promising candidate markers in independent populations has been performed. Studies suggest that risk for subsequent chronic GVHD development may be associated with donor-recipient genetic polymorphism, deficiency in regulatory immune cell populations (NK, Treg, DC2), and variation in inflammatory and immunoregulatory mediators post-HCT (increased TNFa, IL-10 and BAFF, and decreased TGFb and IL-15). Established chronic GVHD is associated with alteration in immune cell populations (increased CD3(+)T cells, Th17, CD4(+) and CD8(+) effector memory cells, monocytes, CD86 expression, BAFF/ B cell ratio, and deficiency of Treg, NK cells, and nai ve CD8(+) T cells). Inflammatory and immunomodulatory factors (TNF alpha, IL-6, IL-1 beta, IL-8, sIL-2R, and IL-1Ra, BAFF, anti-dsDNA, sIL-2R alpha, and sCD13) are also perturbed. Little is known about biologic markers of chronic GVHD phenotype and severity, response to therapy, and prognosis.